Effects of sub-chronic exposure to naturally occuring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice

Journal of Endocrinology

Volumn 191, Issue 1, 2006, Pages 93-100

  Parker, J C ^b   Lavery, K S ^b   Irwin, N ^b   Green, B D ^b   Greer, B ^a   Harriott, P ^a   O'Harte, F P M ^b   Gault, V A ^b   Flatt, P R ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [3-42] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CELL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; IMMUNOCYTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; LONG TERM EXPOSURE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PANCREAS ISLET CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MICE; MICE, OBESE; OBESITY; ORGAN SIZE; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 33751055819     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06904     Document Type: Article

References (36)

1. Abramoff MD, Magelhaes PJ & Ram SJ 2004 Image processing with imageJ. Biophotonics International 11 36-42.
2. Bailey CJ, Flatt PR & Atkins TW 1982 Influence of the genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. International Journal of Obesity 6 11-21.
3. Brown JC, Dahl M, Kwauk S, McIntosh CH, Otte SC & Pederson RA 1981 Actions of GIP. Peptides 2 241-245.
4. Burington RS 1973 Handbook of Mathematical Tables and Formulae. New York: McGraw-Hill.
5. Buteau J, Roduit R & Prentki M 1999 Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42 856-864.
6. Deacon CF, Johnsen AH & Holst JJ 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is an endogenous metabolite in vivo. Journal of Clinical Endocrinology and Metabolism 80 952-957.
7. Deacon CF, Nauck MA, Meier J, Hucking K & Holst JJ 2000 Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. Journal of Clinical Endocrinology and Metabolism 85 3575-3581.
8. Deacon CF, Plamboeck A, Moller S & Holst JJ 2002 GLP-1(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. American Journal of Physiology 282 E873-E879.
9. Deacon CF, Plamboeck A, Rosenkilde MM, De Heer J & Holst JJ 2006 GIP 3-42 does not antagonize the insulinotropic effects of GIP at physiological concentrations. American Journal of Physiology 291 E468-E475.
10. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Gharei MA & Bloom SR 1999 Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48 86-93.
11. Ehses JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth HU, Pederson RA & McIntosh CH 2003 Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation ofp38 mitogen-activated protein kinase. Endocrinology 144 4433-4445.
12. Gault VA, Parker JC, Harriott P, Flatt PR & O'Harte FPM 2002 Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. Journal of Endocrinology 175 525-533.
13. Gault VA, O'Harte FP & Flatt PR 2003a Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 37 253-263.
14. Gault VA, Irwin N, Harriott P, Flatt PR & O'Harte FP 2003b DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP. Cell Biology International 27 41-46.
15. 3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54 2436-2446.
16. Green BD, Gault VA, O'Harte FP & Flair PR 2004a Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Current Pharmaceutical Design 10 3651-3662.
17. 9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)aniide and exendin (9-39). Metabolism 53 252-259.
18. Knudsen LB & Pridal L 1996 Glucagon-like peptide-1-(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. European Journal of Pharmacology 318 429-435.
19. Kolligs F, Fehmann HC, Goke R & Goke B 1995 Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor anatagonist exendin (9-39) amide. Diabetes 44 16-19.
20. Lojda Z, Hermansky F, Benesova E, Salkova J & Lodrova V 1979 Dipeptidylaminopeptidase IV in lymphocytes of peripheral blood of man and the importance of its evidence in malignant lymphomas. Sbornik Lekarsky 81 200-207.
21. Meier JJ, Gallwitz B & Nauck MA 2003 Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs 17 93-102.
22. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE & Gallwitz B 2004 Secretion, degradation, and elimination of glucagon-like pepticle 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53 654-662.
23. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regulatory Peptides 85 9-24.
24. Mentlein R, Gallwitz B & Schmidt WE 1993 Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry 214 829-835.
25. Nauck MA 1999 Is glucagon-like peptide 1 an incretin hormone? Diabetologia 42 373-379.
26. O'Harte FPM, Gray AM & Flatt PR 1998 Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. Journal of Endocrinology 156 237-243.
27. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA & DeMuth HU 1996 Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1(7-36)amide degradation in vitro by dipeptidyl peptidase IV using matrix assisted laser desorption/ ionization-time of flight mass spectrometry. A novel kinetic approach. Journal of Biological Chemistry 271 23222-23229.
28. Rudovich NN, Rochlitz HJ & Pfeiffer AF 2004 Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes 53 2359-2365.
29. Thulesen J, Knudsen LB, Hartmann B, Hastrup, S, Kissow H, Jeppesen PB, Orskov C, Holst JJ & Poulsen SS 2002 The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regulatory Peptides 103 9-15.
30. Trapote MA, Clemente F, Galera C, Morales M, Alcantara AI, Lopez-Delgado MI, Villanueva-Penacarrillo ML & Valverde I 1996 Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver. Journal of Endocrinological Investigation 19 114-118.
31. Trumper A, Trumper K & Horsch D 2002 Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. Journal of Endocrinology 174 233-246.
32. Tseng CC, Zhang XY & Wolfe MM 1999 Effect of GIP and GLP-1 antagonists on insulin release in the rat. American Journal of Physiology 276 E1049-E1054.
33. Vahl TP, Paty BW, Fuller BD, Prigeon RL & D'Alessio DA 2003 Effects of GLP-1(7-36)NH2, GLP-1(7-37), and GLP-1(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. Journal of Clinical Endocrinology and Metabolism 88 1772-1779.
34. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E & Valverde I 1994 Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37 1163-1166.
35. Wrenger S, Reinhold D, Faust J, Mrestani-Klaus C, Brandt W, Fengler A, Neubert K & Ansorge S 2000 Effects of nonapeptides derived from the N-terminal structure of human immunodeficiency virus-1 (HIV-1) Tat on suppression of CD26-dependent T cell growth. Advances in Experimental Medicine and Biology 477 161-165.
36. Yip RG & Wolfe MM 2000 GIP biology and fat metabolism. Life Sciences 66 91-103.